GlassScriptPhysician profile
Christian S Breburda
NPI 1912070608
$35,375.62
in general payments reported to CMS, 2019-2025
46 companies · $534 in 2025
The $534 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,538 · 2020: $8,150 · 2021: $8,446 · 2022: $2,407 · 2023: $4,505 · 2024: $4,795 · 2025: $534.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,788 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,750 · Travel and Lodging: $1,296.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,787.58 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,750.00 |
| Travel and Lodging | $1,295.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ge Healthcare | $8,800.00 | 2020-2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $6,913.43 | 2019-2025 | Lifevest |
| Boston Scientific Corporation | $2,558.21 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $2,196.61 | 2019-2025 | |
| Abbott Laboratories | $1,668.69 | 2019-2023 | Assurity |
| Amgen INC. | $1,650.34 | 2019-2024 | Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,197.72 | 2019-2023 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $1,186.28 | 2019-2024 | Farxiga |
| Impulse Dynamics (USA) INC. | $950.34 | 2021-2023 | Optimizer |
| Biotronik INC. | $803.33 | 2019-2023 | Acticor 7 Vr-T Dx, Biomonitor, Amvia Edge |
| Medtronic Vascular, INC. | $603.49 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $585.12 | 2019-2023 | Xarelto |
| Amarin Pharma, INC. | $584.56 | 2019-2022 | |
| Novo Nordisk INC | $527.13 | 2021-2025 | Wegovy |
| Sanofi-Aventis U.S. LLC | $429.16 | 2019-2023 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christian Breburda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.